Global Pneumonia Vaccine Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Pneumonia Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Pneumonia Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Pneumonia Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Pneumonia Vaccine market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Pneumonia Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Pneumonia Vaccine market include Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Glaxosmithkline Plc., Zhifei Biologic, Walvax Biotechnology, Serum Institute of India Pvt. Ltd., Sanofi Pasteur and Royal (Wuxi) Bio-Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Pneumonia Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Pneumonia Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Pneumonia Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Pneumonia Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Pneumonia Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Pneumonia Vaccine sales, projected growth trends, production technology, application and end-user industry.
Pneumonia Vaccine Segment by Company
Johnson & Johnson
Merck & Co., Inc.
Pfizer Inc.
Glaxosmithkline Plc.
Zhifei Biologic
Walvax Biotechnology
Serum Institute of India Pvt. Ltd.
Sanofi Pasteur
Royal (Wuxi) Bio-Pharmaceutical
Emergent Biosolutions
CSL Limited
Astrazeneca Plc.
Astellas Pharma Inc.
Pneumonia Vaccine Segment by Type
Pneumococcal Conjugate Vaccine (PCV13)
Pneumococcal Polysaccharide Vaccine (PPSV23)
Other
Pneumonia Vaccine Segment by Application
Sepsis
Meningitis
Pneumonia
Pneumonia Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Pneumonia Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Pneumonia Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Pneumonia Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Pneumonia Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumonia Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pneumonia Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumonia Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Pneumonia Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pneumonia Vaccine industry.
Chapter 3: Detailed analysis of Pneumonia Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Pneumonia Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Pneumonia Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Pneumonia Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Pneumonia Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Pneumonia Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Pneumonia Vaccine market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Pneumonia Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Pneumonia Vaccine market include Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Glaxosmithkline Plc., Zhifei Biologic, Walvax Biotechnology, Serum Institute of India Pvt. Ltd., Sanofi Pasteur and Royal (Wuxi) Bio-Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Pneumonia Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Pneumonia Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Pneumonia Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Pneumonia Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Pneumonia Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Pneumonia Vaccine sales, projected growth trends, production technology, application and end-user industry.
Pneumonia Vaccine Segment by Company
Johnson & Johnson
Merck & Co., Inc.
Pfizer Inc.
Glaxosmithkline Plc.
Zhifei Biologic
Walvax Biotechnology
Serum Institute of India Pvt. Ltd.
Sanofi Pasteur
Royal (Wuxi) Bio-Pharmaceutical
Emergent Biosolutions
CSL Limited
Astrazeneca Plc.
Astellas Pharma Inc.
Pneumonia Vaccine Segment by Type
Pneumococcal Conjugate Vaccine (PCV13)
Pneumococcal Polysaccharide Vaccine (PPSV23)
Other
Pneumonia Vaccine Segment by Application
Sepsis
Meningitis
Pneumonia
Pneumonia Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Pneumonia Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Pneumonia Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Pneumonia Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Pneumonia Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumonia Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pneumonia Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumonia Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Pneumonia Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pneumonia Vaccine industry.
Chapter 3: Detailed analysis of Pneumonia Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Pneumonia Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Pneumonia Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
194 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Pneumonia Vaccine Sales Value (2020-2031)
- 1.2.2 Global Pneumonia Vaccine Sales Volume (2020-2031)
- 1.2.3 Global Pneumonia Vaccine Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Pneumonia Vaccine Market Dynamics
- 2.1 Pneumonia Vaccine Industry Trends
- 2.2 Pneumonia Vaccine Industry Drivers
- 2.3 Pneumonia Vaccine Industry Opportunities and Challenges
- 2.4 Pneumonia Vaccine Industry Restraints
- 3 Pneumonia Vaccine Market by Company
- 3.1 Global Pneumonia Vaccine Company Revenue Ranking in 2024
- 3.2 Global Pneumonia Vaccine Revenue by Company (2020-2025)
- 3.3 Global Pneumonia Vaccine Sales Volume by Company (2020-2025)
- 3.4 Global Pneumonia Vaccine Average Price by Company (2020-2025)
- 3.5 Global Pneumonia Vaccine Company Ranking (2023-2025)
- 3.6 Global Pneumonia Vaccine Company Manufacturing Base and Headquarters
- 3.7 Global Pneumonia Vaccine Company Product Type and Application
- 3.8 Global Pneumonia Vaccine Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Pneumonia Vaccine Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Pneumonia Vaccine Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Pneumonia Vaccine Market by Type
- 4.1 Pneumonia Vaccine Type Introduction
- 4.1.1 Pneumococcal Conjugate Vaccine (PCV13)
- 4.1.2 Pneumococcal Polysaccharide Vaccine (PPSV23)
- 4.1.3 Other
- 4.2 Global Pneumonia Vaccine Sales Volume by Type
- 4.2.1 Global Pneumonia Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Pneumonia Vaccine Sales Volume by Type (2020-2031)
- 4.2.3 Global Pneumonia Vaccine Sales Volume Share by Type (2020-2031)
- 4.3 Global Pneumonia Vaccine Sales Value by Type
- 4.3.1 Global Pneumonia Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Pneumonia Vaccine Sales Value by Type (2020-2031)
- 4.3.3 Global Pneumonia Vaccine Sales Value Share by Type (2020-2031)
- 5 Pneumonia Vaccine Market by Application
- 5.1 Pneumonia Vaccine Application Introduction
- 5.1.1 Sepsis
- 5.1.2 Meningitis
- 5.1.3 Pneumonia
- 5.2 Global Pneumonia Vaccine Sales Volume by Application
- 5.2.1 Global Pneumonia Vaccine Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Pneumonia Vaccine Sales Volume by Application (2020-2031)
- 5.2.3 Global Pneumonia Vaccine Sales Volume Share by Application (2020-2031)
- 5.3 Global Pneumonia Vaccine Sales Value by Application
- 5.3.1 Global Pneumonia Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Pneumonia Vaccine Sales Value by Application (2020-2031)
- 5.3.3 Global Pneumonia Vaccine Sales Value Share by Application (2020-2031)
- 6 Pneumonia Vaccine Regional Sales and Value Analysis
- 6.1 Global Pneumonia Vaccine Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Pneumonia Vaccine Sales by Region (2020-2031)
- 6.2.1 Global Pneumonia Vaccine Sales by Region: 2020-2025
- 6.2.2 Global Pneumonia Vaccine Sales by Region (2026-2031)
- 6.3 Global Pneumonia Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Pneumonia Vaccine Sales Value by Region (2020-2031)
- 6.4.1 Global Pneumonia Vaccine Sales Value by Region: 2020-2025
- 6.4.2 Global Pneumonia Vaccine Sales Value by Region (2026-2031)
- 6.5 Global Pneumonia Vaccine Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Pneumonia Vaccine Sales Value (2020-2031)
- 6.6.2 North America Pneumonia Vaccine Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Pneumonia Vaccine Sales Value (2020-2031)
- 6.7.2 Europe Pneumonia Vaccine Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Pneumonia Vaccine Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Pneumonia Vaccine Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Pneumonia Vaccine Sales Value (2020-2031)
- 6.9.2 South America Pneumonia Vaccine Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Pneumonia Vaccine Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Pneumonia Vaccine Sales Value Share by Country, 2024 VS 2031
- 7 Pneumonia Vaccine Country-level Sales and Value Analysis
- 7.1 Global Pneumonia Vaccine Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Pneumonia Vaccine Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Pneumonia Vaccine Sales by Country (2020-2031)
- 7.3.1 Global Pneumonia Vaccine Sales by Country (2020-2025)
- 7.3.2 Global Pneumonia Vaccine Sales by Country (2026-2031)
- 7.4 Global Pneumonia Vaccine Sales Value by Country (2020-2031)
- 7.4.1 Global Pneumonia Vaccine Sales Value by Country (2020-2025)
- 7.4.2 Global Pneumonia Vaccine Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.9.2 France Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.16.2 China Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.19.2 India Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Pneumonia Vaccine Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Pneumonia Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Pneumonia Vaccine Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Johnson & Johnson
- 8.1.1 Johnson & Johnson Comapny Information
- 8.1.2 Johnson & Johnson Business Overview
- 8.1.3 Johnson & Johnson Pneumonia Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Johnson & Johnson Pneumonia Vaccine Product Portfolio
- 8.1.5 Johnson & Johnson Recent Developments
- 8.2 Merck & Co., Inc.
- 8.2.1 Merck & Co., Inc. Comapny Information
- 8.2.2 Merck & Co., Inc. Business Overview
- 8.2.3 Merck & Co., Inc. Pneumonia Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Merck & Co., Inc. Pneumonia Vaccine Product Portfolio
- 8.2.5 Merck & Co., Inc. Recent Developments
- 8.3 Pfizer Inc.
- 8.3.1 Pfizer Inc. Comapny Information
- 8.3.2 Pfizer Inc. Business Overview
- 8.3.3 Pfizer Inc. Pneumonia Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Pfizer Inc. Pneumonia Vaccine Product Portfolio
- 8.3.5 Pfizer Inc. Recent Developments
- 8.4 Glaxosmithkline Plc.
- 8.4.1 Glaxosmithkline Plc. Comapny Information
- 8.4.2 Glaxosmithkline Plc. Business Overview
- 8.4.3 Glaxosmithkline Plc. Pneumonia Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Glaxosmithkline Plc. Pneumonia Vaccine Product Portfolio
- 8.4.5 Glaxosmithkline Plc. Recent Developments
- 8.5 Zhifei Biologic
- 8.5.1 Zhifei Biologic Comapny Information
- 8.5.2 Zhifei Biologic Business Overview
- 8.5.3 Zhifei Biologic Pneumonia Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Zhifei Biologic Pneumonia Vaccine Product Portfolio
- 8.5.5 Zhifei Biologic Recent Developments
- 8.6 Walvax Biotechnology
- 8.6.1 Walvax Biotechnology Comapny Information
- 8.6.2 Walvax Biotechnology Business Overview
- 8.6.3 Walvax Biotechnology Pneumonia Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Walvax Biotechnology Pneumonia Vaccine Product Portfolio
- 8.6.5 Walvax Biotechnology Recent Developments
- 8.7 Serum Institute of India Pvt. Ltd.
- 8.7.1 Serum Institute of India Pvt. Ltd. Comapny Information
- 8.7.2 Serum Institute of India Pvt. Ltd. Business Overview
- 8.7.3 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Product Portfolio
- 8.7.5 Serum Institute of India Pvt. Ltd. Recent Developments
- 8.8 Sanofi Pasteur
- 8.8.1 Sanofi Pasteur Comapny Information
- 8.8.2 Sanofi Pasteur Business Overview
- 8.8.3 Sanofi Pasteur Pneumonia Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Sanofi Pasteur Pneumonia Vaccine Product Portfolio
- 8.8.5 Sanofi Pasteur Recent Developments
- 8.9 Royal (Wuxi) Bio-Pharmaceutical
- 8.9.1 Royal (Wuxi) Bio-Pharmaceutical Comapny Information
- 8.9.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
- 8.9.3 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Product Portfolio
- 8.9.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
- 8.10 Emergent Biosolutions
- 8.10.1 Emergent Biosolutions Comapny Information
- 8.10.2 Emergent Biosolutions Business Overview
- 8.10.3 Emergent Biosolutions Pneumonia Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Emergent Biosolutions Pneumonia Vaccine Product Portfolio
- 8.10.5 Emergent Biosolutions Recent Developments
- 8.11 CSL Limited
- 8.11.1 CSL Limited Comapny Information
- 8.11.2 CSL Limited Business Overview
- 8.11.3 CSL Limited Pneumonia Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.11.4 CSL Limited Pneumonia Vaccine Product Portfolio
- 8.11.5 CSL Limited Recent Developments
- 8.12 Astrazeneca Plc.
- 8.12.1 Astrazeneca Plc. Comapny Information
- 8.12.2 Astrazeneca Plc. Business Overview
- 8.12.3 Astrazeneca Plc. Pneumonia Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.12.4 Astrazeneca Plc. Pneumonia Vaccine Product Portfolio
- 8.12.5 Astrazeneca Plc. Recent Developments
- 8.13 Astellas Pharma Inc.
- 8.13.1 Astellas Pharma Inc. Comapny Information
- 8.13.2 Astellas Pharma Inc. Business Overview
- 8.13.3 Astellas Pharma Inc. Pneumonia Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.13.4 Astellas Pharma Inc. Pneumonia Vaccine Product Portfolio
- 8.13.5 Astellas Pharma Inc. Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Pneumonia Vaccine Value Chain Analysis
- 9.1.1 Pneumonia Vaccine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Pneumonia Vaccine Sales Mode & Process
- 9.2 Pneumonia Vaccine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Pneumonia Vaccine Distributors
- 9.2.3 Pneumonia Vaccine Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


